Clinical trials: Multicentric Castleman Disease
Multicentric Castleman's Disease
A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease
The purpose of this study is to demonstrate that CNTO 328 when administered in combination with best supportive care (BSC) is superior to BSC in terms of durable tumor and symptomatic response (complete response or partial…
- Trial name
- NCT01024036
- Testing
- Siltuximab, Best Supportive Care (BSC)
- Where
- 56 sites in United States, Australia and 21 more
- Volunteers
- 79 people
- Sponsor
- Janssen Research & Development, LLC
Idiopathic Multicentric Castleman's Disease
Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease
Phase 2 study to investigate the safety, tolerability, and efficacy of administering increased siltuximab doses to patients with iMCD
- Trial name
- SISREMCAD (NCT04838860)
- Testing
- Siltuximab
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- RECORDATI GROUP
Idiopathic Multicentric Castleman's Disease
Producing a Novel Symptom Burden Scale for People Living With Idiopathic Multicentric Castleman Disease (ISBUS)
Development, validation of a novel symptom burden scale to assess and quantify the burden experienced by people living with Idiopathic Multicentric Castleman Disease (iMCD).
- Trial name
- NCT05995834
- Testing
- Research questions
- Volunteers
- 100 people
- Sponsor
- RECORDATI GROUP
Idiopathic Multicentric Castleman's Disease
A Study of Anti-IL-6R mAb Injection in Patients With iMCD
This study is a single-arm, open-label, multicenter, dose-escalation clinical study. Its primary purpose is to evaluate the safety and tolerability of recombinant humanized anti-interleukin-6 receptor monoclonal antibody …
- Trial name
- NCT05345522
- Testing
- Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4 mg/kg, q2w, Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6 mg/kg, q2w, Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 8 mg/kg, q2w
- Where
- 3 sites in China
- Volunteers
- 25 people
- Sponsor
- Beijing VDJBio Co., LTD.
Multicentric Castleman's Disease
A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease
The purpose of this study is to evaluate the long-term safety of siltuximab in patients with multicentric Castleman's disease (MCD).
- Trial name
- NCT01400503
- Testing
- Siltuximab
- Where
- 26 sites in United States, Belgium and 15 more
- Volunteers
- 60 people
- Sponsor
- Janssen Research & Development, LLC
Anti IL-6R, Castleman's Disease, Multicentric
Phase III Trial of VDJ001 In Patients With Idiopathic Multicentric Castleman Disease
This study adopted a multicenter, randomized, double-blind, placebo-controlled approach with the best supportive treatment design, using recombinant humanized anti-interleukin-6 receptor monoclonal antibody injection (VDJ001) to…
- Trial name
- NCT07872423
- Testing
- Recombinant Humanized Anti-Interleukin-6 Receptor Monoclonal Antibody Injection
- Where
- 8 sites in China
- Volunteers
- 45 people
- Sponsor
- Beijing VDJBio Co., LTD.
Castleman's Disease
A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment
This open-label, single center study will provide RoActemra/Actemra (tocilizumab) to a maximum of 4 patients with Multicentric Castelman's Disease who have demonstrated benefit from RoActemra/Actemra in study MRA004US (Chugai…
- Trial name
- NCT01183598
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Hoffmann-La Roche